Abstract
The new therapeutic modalities in psoriatic arthritis have been represented by the biologic therapy. This brings the breakthrough in the treatment of this disease, rather that all these medicaments besides favourable affect on arthritis, they at the same time favourably affect psoriasis, enthesitis and above all they slow down, or even halt X-ray progression.
At present most experience is with infliximab, etanercept and adalimumab. Soon new anti-TNFα drugs are expected to arrive at the market – golimumab and certolizumab.
Another approach to biologic therapy is represented by an attempt to influence the activation of T.cells at the level of the T-cell receptor (TCR), the so called costimulatory molecules, inhibition of T-cells proliferation / damage, or through the immunomodulation. Some of these drugs are allready registrered, the clinical studies of others are pending.